Search / 18 results found

from
to
  • Updated

RADNOR, Pa., Aug. 30, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) announced an additional finding in its phase 2b/3 clinical trial investigating ZYESAMI™ (aviptadil) for the treatment of patients with acute Respiratory Failure due to Critical COVID-19. Previously announced results have focused on survival and recovery from respiratory failure at 60 days, and ZYESAMI's apparent role in preventing rise in the inflammatory cytokine IL-6, known as "Cytokine Storm."

Vaping has come of age in the most perfect of social conditions. Smoking cigarettes is falling out of favor socially and even among nicotine users, and is wholly rejected by many young people today. To get their fix they're turning to what is marketed as a cleaner and safer method of ingestion. Enticing flavors, edgy technology and social media are empowering the tobacco industry to ensnare a new generation with nicotine addiction
by way of vaping. And it’s working. In 2016, 43.8% of high schoolers in New York state tried vaping, more than double the total two years prior. This trend has Ontario County officials deeply concerned.